Proof-of-Concept Study with BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults with Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, To ...
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults With Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, To ...
Rheumatoid Arthritis
Drug: Placebo;Drug: BMS-817399
Bristol-Myers Squibb
NULL
Completed
18 Years
N/A
Both
123
Phase 2
United States;Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain